All posts by: Michael Zand

About Michael Zand

A Harvard startup is using gene therapy to reverse ageing in dogs, humans are next – Moneycontrol.com

Continue reading

2018-05-14 NEWS

Moneycontrol.com

A Harvard startup is using gene therapy to reverse ageing in dogs, humans are next
Moneycontrol.com
In order to achieve the objective to “have the body and mind of a 22-year-old but the experience of a 130-year-old,” a Harvard professor backed startup is planning to rejuvenate dogs using gene therapy. And, if results are positive, the same approach
Harvard startup aims to reverse aging in dogs, and possibly humansBusiness Insider India
Harvard startup aims to ‘reverse aging’ in dogs, humans could be nextTHE WEEK

all 5 news articles »

Continue reading

2018-05-14 NEWS

Drug Target Review

CRISPR used to restore retinal function
Drug Target Review
Researchers from Columbia University have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice afflicted by a degenerative retinal disease, retinitis pigmentosa. This is the first time researchers have …
New technique may help patients overcome various eye diseasesDeccan Chronicle
A new ‘vision’The Asian Age

all 3 news articles »

Continue reading

2018-05-14 NEWS

Herald Sun

Mini organs grown for stem cell test hoped to cure fatal disease in premature babies
Herald Sun
The team’s preclinical studies have shown that amnion cells taken from the placenta can support the bowel’s own stem cells to repair itself. If the team is able to grow and then treat “mini bowels” with stem cells, they would then test whether breast

Continue reading

2018-05-14 NEWS

PR Web (press release)

ASGCT To Honor Four Ground-Breaking Researchers at 21st Annual Meeting
PR Web (press release)
The American Society of Gene and Cell Therapy (ASGCT) will honor four groundbreaking researchers and advocates as part of the Society’s 21st Annual Meeting, held at the Chicago Hilton this week. The presentation of these four awards represents the …

and more »

Continue reading

2018-05-14 NEWS

Xconomy

Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
Xconomy
Xconomy Boston —. The founders of CRISPR-Cas9 startup Editas Medicine have gotten a jump on the next version of CRISPR gene editing. Scientists from Harvard University, Massachusetts General Hospital, and the Broad Institute are behind Beam …
Feng Zhang’s base-editing CRISPR startup officially launches with $87MFierceBiotech
A pencil, not a pair of scissors: CRISPR pioneers’ new company bets on base editing to cure diseaseSTAT
CRISPR trailblazers Zhang, Liu and Joung join forces to launch Beam with $87M and cutting-edge gene-editing techEndpoints News
MIT Technology Review –Financial Times –Business Insider
all 9 news articles »